Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Adverse Business Impact

Piramal Pharma Adverse Business Impact

Piramal Pharma announced that its sales and distribution arrangement with Bayer Pharmaceuticals will expire on December 31, 2026, and will not be renewed.

Key figures
Order fromBayer Pharmaceuticals Private Limited
Source

BSE filing, NSE: PPLPHARMA. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Piramal Pharma Ltd: key numbers

Share price
₹232.80
Market cap
₹30,994 Cr
Revenue (annual)
₹8,869 Cr
Net profit (annual)
₹-325.9 Cr
P/E (TTM)
-148.4×Sector 46.1×
Promoter holding
34.80%+0.00% QoQ
FII holding
13.65%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Piramal Pharma Ltd

All →

Other adverse business impact announcements

All →